ES2039773T3 - Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus. - Google Patents

Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus.

Info

Publication number
ES2039773T3
ES2039773T3 ES89114617T ES89114617T ES2039773T3 ES 2039773 T3 ES2039773 T3 ES 2039773T3 ES 89114617 T ES89114617 T ES 89114617T ES 89114617 T ES89114617 T ES 89114617T ES 2039773 T3 ES2039773 T3 ES 2039773T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
treatment
preparing
procedure
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89114617T
Other languages
English (en)
Spanish (es)
Inventor
Michael Dr Dorschug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2039773T3 publication Critical patent/ES2039773T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES89114617T 1988-08-13 1989-08-08 Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus. Expired - Lifetime ES2039773T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3827533A DE3827533A1 (de) 1988-08-13 1988-08-13 Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Publications (1)

Publication Number Publication Date
ES2039773T3 true ES2039773T3 (es) 1996-07-16

Family

ID=6360797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89114617T Expired - Lifetime ES2039773T3 (es) 1988-08-13 1989-08-08 Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus.

Country Status (18)

Country Link
US (1) US5177058A (enExample)
EP (1) EP0357978B1 (enExample)
JP (1) JPH02101022A (enExample)
KR (1) KR900002801A (enExample)
AT (1) ATE75945T1 (enExample)
AU (1) AU621648B2 (enExample)
CA (1) CA1332354C (enExample)
DE (2) DE3827533A1 (enExample)
DK (1) DK395689A (enExample)
ES (1) ES2039773T3 (enExample)
FI (1) FI95202C (enExample)
GR (1) GR3005326T3 (enExample)
HU (1) HU203670B (enExample)
IE (1) IE61266B1 (enExample)
NO (1) NO178914C (enExample)
NZ (1) NZ230280A (enExample)
PT (1) PT91420B (enExample)
ZA (1) ZA896149B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE4024434A1 (de) * 1990-08-01 1992-02-13 Fresenius Ag Vorrichtung zur ultrafiltrationskontrolle bzw. ultrafiltrationsregelung bei blutreinigungsverfahren
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
ES2218622T3 (es) * 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20050014679A1 (en) * 2001-12-20 2005-01-20 Beals John Michael Insulin molecule having protracted time action
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CA2518776A1 (en) * 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
JP4463814B2 (ja) * 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
CN101389650B (zh) * 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
CN101677947B (zh) * 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
CN101939023B (zh) * 2007-10-16 2016-08-03 百康有限公司 可经口给药的固体药物组合物及其方法
BRPI0920881B1 (pt) 2008-10-17 2021-09-21 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
JP4959005B2 (ja) * 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー/エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー/エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
BR112017012406A2 (pt) 2014-12-12 2018-07-31 Sanofi Aventis Deutschland formulação com relação fixa de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP3996679B1 (en) 2019-07-12 2023-09-06 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2143591A (en) * 1936-09-26 1939-01-10 Univ Alberta Therapeutic preparation and process of making and using it
US2354211A (en) * 1940-07-02 1944-07-25 Burroughs Wellcome Co Insulin preparation
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3334407A1 (de) * 1983-09-23 1985-04-04 Hoechst Ag, 6230 Frankfurt In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider

Also Published As

Publication number Publication date
JPH02101022A (ja) 1990-04-12
EP0357978A1 (de) 1990-03-14
DK395689D0 (da) 1989-08-11
ATE75945T1 (de) 1992-05-15
GR3005326T3 (enExample) 1993-05-24
IE892594L (en) 1990-02-13
US5177058A (en) 1993-01-05
PT91420A (pt) 1990-03-08
DE58901401D1 (de) 1992-06-17
HUT50443A (en) 1990-02-28
FI95202C (fi) 1996-01-10
FI893783L (fi) 1990-02-14
NO178914B (no) 1996-03-25
AU621648B2 (en) 1992-03-19
FI893783A0 (fi) 1989-08-10
KR900002801A (ko) 1990-03-23
PT91420B (pt) 1995-05-04
EP0357978B1 (de) 1992-05-13
CA1332354C (en) 1994-10-11
FI95202B (fi) 1995-09-29
NZ230280A (en) 1991-09-25
ZA896149B (en) 1990-04-25
AU3951489A (en) 1990-02-15
NO893239L (no) 1990-02-14
DE3827533A1 (de) 1990-02-15
IE61266B1 (en) 1994-10-19
HU203670B (en) 1991-09-30
NO178914C (no) 1996-07-03
DK395689A (da) 1990-02-14
NO893239D0 (no) 1989-08-11

Similar Documents

Publication Publication Date Title
ES2039773T3 (es) Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus.
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
PH23014A (en) Novel insulin derivatives,their use and pharmaceutical agents for the treatment of diabetes mellitus
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
IT1236688B (it) Procedimento e dispositivo per la creazione di una miscela combustibile-aria comburente da addurre a una combustione.
ES2195220T3 (es) Acidos sulfonilaminocarboxilicos.
DE3679908D1 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
FI95539C (fi) Transdermaalinen järjestelmä, sen valmistusmenetelmä ja käyttö
ES2165640T3 (es) Acidos diaminocarboxilicos sustituidos.
ES2035086T3 (es) Procedimiento para preparar una composicion solida y estable que contiene ibuprofeno y codeina.
AR004486A1 (es) Uso de tripicolinato cromico en la preparacion de un medicamento
FI886019A7 (fi) Laastari vaikuttavien aineiden valvotusti jakamiseksi iholle
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
DE3887338D1 (de) Superaktive menschliche insulin-analoge.
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
SE8204873D0 (sv) Farmaceutiska preparat, innefattande humant insulin och human c-peptid
DE69015910D1 (de) Pharmazeutische Verwendung von Fettsäuren.
ATE125805T1 (de) Furanderivate.
KR940005283A (ko) 활성 성분으로 글리센틴을 함유하는 약제
ATE124627T1 (de) Diclofenac-natrium enthaltende pharmazeutische zusammensetzung zur topischen anwendung.
DE3880561D1 (de) Actinoninderivate mit physiologischen aktivitaeten.
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
DE3877365D1 (de) Arzneimittel mit methylcellulose.
ES2059633T3 (es) 2-terc.-butil-4-cloro-5-(4-terc.-butilbenciltio)-3(2h)-piridazinona para la lucha contra los moluscos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 357978

Country of ref document: ES

FG2A Definitive protection

Ref document number: 0357978

Country of ref document: ES